Phase 3 REFLECT Trial in Patients with Unresectable Hepatocellular Carcinoma

An expert in hematology-oncology provides key insights into treatment considerations for patients with hepatocellular carcinoma and reviews safety and efficacy data from the phase 3 REFLECT Trial of lenvatinib for patients with unresectable disease.

EP. 1: An Overview of Hepatocellular Carcinoma

July 20th 2021

An expert in hematology-oncology, Richard S. Finn, MD, provides an overview of hepatocellular carcinoma by discussing its prevalence, patient risk factors, and overall prognosis.

EP. 2: Defining Unresectable and Advanced HCC

July 20th 2021

Richard S. Finn, MD defines unresectable or advanced hepatocellular carcinoma by discussing venous invasion, extrahepatic spread, and progression after locoregional treatments.

EP. 3: The REFLECT Study of Lenvatinib for Unresectable HCC

July 20th 2021

A key opinion leader in liver cancer reviews the study design of the REFLECT trial of lenvatinib in patients with HCC and shares key insights into its safety and efficacy data.

EP. 4: Lenvatinib Combination Therapy for Treatment of HCC

July 20th 2021

An expert hematologist-oncologist considers the potential role of combination therapy with lenvatinib for patients with hepatocellular carcinoma.

EP. 5: Clinical Trials of Lenvatinib Combination Therapy

July 20th 2021

A thought leader in the management of hepatocellular carcinoma provides an overview of several clinical trials of combination therapy with lenvatinib including studies of real-world evidence and potential biomarkers.

EP. 6: Future Directions in Systemic Treatment of HCC

July 20th 2021

Richard S. Finn, MD concludes the discussion by commenting on areas of unmet need in the care of HCC and emphasizes the potential impact of trials studying treatment combination and sequencing.